---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019124"
form_type: "8-K"
ticker: "CYCN"
cik: "0001755237"
company_name: "Cyclerion Therapeutics, Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:26:18.061860+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CSO Andreas Busch resigns effective Sept 30, 2022

## Summary
- Andreas Busch, Ph.D. resigned as Chief Scientific Officer, effective Sept 30, 2022.
- Dr. Busch left to pursue another opportunity; no disagreement with Company's operations, policies or practices.
- No successor has been named; search process not disclosed.

## SEC filing metadata
- accession: 0000950170-22-019124
- form_type: 8-K
- ticker: CYCN
- cik: 0001755237
- company_name: Cyclerion Therapeutics, Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1755237/000095017022019124/0000950170-22-019124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1755237/000095017022019124/cycn-20220930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019124
- JSON: https://secwatch.observer/filing/0000950170-22-019124.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019124.txt

## Key facts
- Executive change
  Andreas Busch, Ph.D. resigned as Chief Scientific Officer at Cyclerion Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On and effective September 30, 2022, Andreas Busch, Ph.D. resigned from his position as Chief Scientific Officer of Cyclerion Therapeutics, Inc. (the “Company”) to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1755237/000095017022019124/0000950170-22-019124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.